Premium
Characterization of in vivo suppression of syngenic tumor by allogenic effector cells
Author(s) -
Sugarbaker Paul H.,
Sugarbaker Stephen P.,
Pun Pattle P.
Publication year - 1980
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.2930150314
Subject(s) - syngenic , cytotoxic t cell , splenocyte , effector , in vivo , cancer research , immune system , in vitro , immunology , biology , medicine , microbiology and biotechnology , biochemistry
The purpose of this study was to characterize the effects of allogenic splenocytes transferred with tumor cells, subcutaneously, to a host syngenic for tumor cells. Cytotoxic effector cells usually resulted in tumors less than half the size of controls at E:T of 10:1. Primary immune splenocytes were more effective than hyperimmune splenocytes in delaying tumor growth. Actively cytotoxic splenocytes by in vitro 51 Cr release assay were required for delayed tumor growth; memory cell populations were not effective. Delayed tumor growth correlated with in vitro cytotoxicity of primary immune splenocytes; however, hyperimmune splenocytes, even though they possessed greater in vitro cytotoxic responses, showed lesser tumor suppression in vivo. T cells were necessary for tumor suppresion, as treatment of B6AF1 effector cells with anti‐Thy 1.2 serum abrogated suppression; T cell enrichement by nylon‐wool treatment of effector cells increased tumor suppression. Delay in tumor growth was an in vivo phenomenon, for anti‐Thy 1.2 serum in AKR hosts abrogated the effect of Thy 1.2 effector cells.